<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC10841595</article-id>
        <article-id pub-id-type="pmcid-ver">PMC10841595.319</article-id>
        <article-id pub-id-type="pmcaid">10841595</article-id>
        <article-id pub-id-type="pmcaiid">10841595</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1948277</article-id>
        <article-id pub-id-type="pmid">37910594</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-23-1180</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1948277</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1948277</article-id>
        <article-version article-version-type="pmc-version">319</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bhatia</surname>
              <given-names initials="A">Ankush</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A2" ref-type="aff">2</xref>
            <xref rid="FN1" ref-type="author-notes">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Moreno</surname>
              <given-names initials="R">Raquel</given-names>
            </name>
            <xref rid="A3" ref-type="aff">3</xref>
            <xref rid="FN1" ref-type="author-notes">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Reiner</surname>
              <given-names initials="AS">Anne S</given-names>
            </name>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nandakumar</surname>
              <given-names initials="S">Subhiksha</given-names>
            </name>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Walch</surname>
              <given-names initials="HS">Henry S</given-names>
            </name>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Thomas</surname>
              <given-names initials="TM">Teena M</given-names>
            </name>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nicklin</surname>
              <given-names initials="PJ">Philip J</given-names>
            </name>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Choi</surname>
              <given-names initials="Y">Ye</given-names>
            </name>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Skakodub</surname>
              <given-names initials="A">Anna</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Malani</surname>
              <given-names initials="R">Rachna</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Prabhakaran</surname>
              <given-names initials="V">Vivek</given-names>
            </name>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tiwari</surname>
              <given-names initials="P">Pallavi</given-names>
            </name>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Diaz</surname>
              <given-names initials="M">Maria</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Panageas</surname>
              <given-names initials="KS">Katherine S.</given-names>
            </name>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mellinghoff</surname>
              <given-names initials="IK">Ingo K</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bale</surname>
              <given-names initials="TA">Tejus A</given-names>
            </name>
            <xref rid="A6" ref-type="aff">6</xref>
            <xref rid="FN2" ref-type="author-notes">^</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Young</surname>
              <given-names initials="RJ">Robert J</given-names>
            </name>
            <xref rid="A3" ref-type="aff">3</xref>
            <xref rid="FN2" ref-type="author-notes">^</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, New York.</aff>
        <aff id="A2"><label>2</label>Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI.</aff>
        <aff id="A3"><label>3</label>Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York.</aff>
        <aff id="A4"><label>4</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York.</aff>
        <aff id="A5"><label>5</label>Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI.</aff>
        <aff id="A6"><label>6</label>Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York.</aff>
        <author-notes>
          <corresp id="CR1"><bold>Corresponding author:</bold> Ankush Bhatia, MD, 7275 UW Medical Foundation, Centennial Building (MFCB), 1685 Highland Avenue, Madison, WI 53705. Phone: 608-263-5448; <email>bhatia@neurology.wisc.edu</email></corresp>
          <fn fn-type="equal" id="FN1">
            <label>*</label>
            <p id="P1">Ankush Bhatia and Raquel Moreno contributed equally as co-first authors.</p>
          </fn>
          <fn fn-type="equal" id="FN2">
            <label>^</label>
            <p id="P2">Tejus A Bale and Robert J Young contributed equally as co-senior authors.</p>
          </fn>
          <fn fn-type="COI-statement" id="FN3">
            <p id="P37">Conflict of interest disclosure statement:</p>
            <p id="P38">Ankush Bhatia, Raquel Moreno, Anne S Reiner, Subhiksha Nandakumar, Henry S Walch, Teena M Thomas, Philip J Nicklin, Ye Choi, Anna Skakodua, Rachna Malani, Maria Diaz, Vivek Prabhakaran, Pallavi Tiwari, and Tejus Bale have no COI to disclose. Robert J Young has consulted for ICON plc, NordicNeuroLab, Olea Sphere, and owns stock in Agios. Katherine S. Panageas receives funding from AACR Project GENIE. Ingo K Mellinghoff reports serving as a consultant for 501c3 Global Coalition for Adaptive Research; reports honoraria from the Doris Duke Charitable Foundation; reports serving on advisory board for Black Diamond Therapeutics, Roche Therapeutics, Prelude Therapeutics Incorporated, Voyager Therapeutics; reports research support from Erasca Therapeutics, Servier Pharmaceuticals LLC, Kazia Therapeutics, Vigeo Therapeutics, and Samus Therapeutics, Inc</p>
          </fn>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>05</day>
          <month>1</month>
          <year>2024</year>
        </pub-date>
        <volume>30</volume>
        <issue>1</issue>
        <issue-id pub-id-type="pmc-issue-id">455061</issue-id>
        <fpage>106</fpage>
        <lpage>115</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>20</day>
              <month>12</month>
              <year>2023</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>05</day>
              <month>07</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>05</day>
              <month>07</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-07-05 00:25:12.273">
              <day>05</day>
              <month>07</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1948277.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Purpose:</title>
            <p id="P3">Isocitrate-dehydrogenase-mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate (TVGR) on magnetic resonance imaging may act as an earlier measure of clinical benefit during the active surveillance period.</p>
          </sec>
          <sec id="S2">
            <title>Experimental Design:</title>
            <p id="P4">We integrated 3-dimensional volumetric measurements with clinical, radiological, and molecular data in a retrospective cohort of IDH-mt gliomas that were observed after surgical resection in order to understand tumor growth kinetics and the impact of molecular genetics.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P5">Using log-linear mixed modeling, the entire cohort (n=128) had a continuous %TVGR per 6 months of 10.46% (95% CI: [9.11%, 11.83%]) and a doubling time of 3.5 years (95% CI: [3.10-3.98]). High molecular grade IDH-mt gliomas, defined by the presence of homozygous deletion of CDKN2A/B, had %TVGR per 6 months of 19.17% (95% CI: [15.57%, 22.89%]) which was significantly different from low molecular grade IDH-mt gliomas with a growth rate per 6 months of 9.54% (95% CI: [7.32%, 11.80%]) (<italic toggle="yes">P</italic> &lt; 0.0001). Using joint modeling to co-model the longitudinal course of TVGR and overall survival, we found each one natural logarithm tumor volume increase resulted in more than a 3-fold increase in risk of death (HR=3.83, 95% CI: [2.32-6.30], <italic toggle="yes">P</italic> &lt; 0.0001).</p>
          </sec>
          <sec id="S4">
            <title>Conclusions:</title>
            <p id="P6">TVGR may be used as an earlier measure of clinical benefit and correlates well with the WHO 2021 molecular classification of gliomas and survival. Incorporation of TVGR as a surrogate endpoint into future prospective studies of IDH-mt gliomas may accelerate drug development.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>neuro-oncology</kwd>
          <kwd>genomics</kwd>
          <kwd>glioma</kwd>
          <kwd>tumor volume</kwd>
          <kwd>surrogate endpoint</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
